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A principal goal of synthetic biology is the de novo design or redesign of
biomolecular components. In addition to revealing fundamentally important
information regarding natural biomolecular engineering and biochemistry,
functional building blocks will ultimately be provided for applications
including the manufacture of valuable products and therapeutics. To fully
realize this ambitious goal, the designed components must be biocompati-
ble, working in concert with natural biochemical processes and pathways,
while not adversely affecting cellular function. For example, de novo protein
design has provided us with a wide repertoire of structures and functions,
including those that can be assembled and function in vivo. Here we discuss
such biocompatible designs, as well as others that have the potential
to become biocompatible, including non-protein molecules, and routes to
achieving full biological integration.1. Introduction
Designed biomolecular and synthetic components that reproduce or even super-
sede the functions and activities of natural proteins and enzymes promise to
revolutionize synthetic biology, industrial biotechnology and medicine [1,2].
While Nature has undoubtedly provided us with a rich diversity of natural bio-
molecules, they might not be well adapted for a selected purpose or
environment outside of their preferred cellular milieu [3,4]. With artificial com-
ponents such as de novo proteins, their sequence, structure and biophysical
characteristics are selected solely by the designer, conferring, for instance, greater
thermal and chemical stability than their natural equivalents and rendering them
better suited to our requirements. Chemical activities unknown in Nature may be
imposed upon them [5], imparting unique reactivities that may be integrated into
the biochemical processes of living organisms. Such endeavours not only result
in useful biomolecular or artificial componentry, but also provide powerful,
fundamental insights into the engineering of natural biomolecules.
This review focuses on artificial components that are, or have the potential to
become, biocompatible. To be defined as biocompatible a component must
efficiently perform an intended role in vivo and at least be able to interact in a
complementary manner with cells or natural biomolecular components. To
satisfy a more stringent definition of biocompatibility, the components—or the
biosynthetic pathway that produces them—should be genetically encoded or
imported directly into the cell, and they should be fully assembled and functional
in vivo, without any significant deleterious effects. For cofactor-dependent pro-
teins and enzymes, this inevitably requires post-translational insertion of small
molecules such as hemes and flavins to impart the desired functionality.
With such biocompatible components, there is then an opportunity to design
systems where natural and synthetic components work synergistically to expand
the range of possibilities offered by entirely natural or entirely synthetic systems
[6]. Syntheticmolecules that can be produced by living organisms also present the
rsif.royalsocietypublishing.org
J.R.Soc.Interfac
2
 on September 14, 2018http://rsif.royalsocietypublishing.org/Downloaded from possibility of ‘eco-friendly’ manufacturing, negating the need
for expensive synthetic processes [4].
Translating a particular function from a natural protein
to a synthetic element is a challenge, and achieving biocompat-
ibility is a further hurdle due to the immense complexity,
diversity and specificity of cellular processes [7]. Currently,
the components that most fulfil these requirements are de
novo designed proteins, although there are other chemical
entities that, with further development, could become biocom-
patible. Herewewill discuss recent developments in the design
of de novo proteins and non-natural elements that reproduce
natural biomolecular functions, with a particular focus on bio-
compatibility. This review is not intended to be exhaustive, but
keyexamples have been selected to illustrate the topics covered.
We will also look to the future and highlight research that lays
the groundwork towards the use of synthetic elements in vivo. e
15:201804722. Protein scaffold design
Before function can be conferred onto an artificial protein,
robust yet mutatable protein scaffolds must be designed.
These proteins may directly mimic existing, natural struc-
tures, or adopt completely new folds. Simplicity and
tolerance to mutations are key to designing a protein scaffold;
a protein that is highly tolerant to mutation while largely
retaining its tertiary structure allows the designer to alter
or improve function in a tractable and facile manner. A
well-defined structure and amenability to characterization
techniques are obviously ideal in such a process, though
the ability to design and predict de novo protein structures
with atomic detail remains a significant challenge [1]. It is
also not always easy to predict how changes to a protein’s
amino acid sequence might affect its stability, structure and
function, therefore simplicity is key. For this reason, the rede-
sign of natural proteins may not be the simplest approach to
achieving new function, although this has been a fruitful area
of research.
The complex network of interactions found in natural pro-
teins has arisen through millennia of natural selection. These
networks arise as amino acids within the protein become irre-
versibly co-dependent, resulting in a Muller’s ratchet-like
accumulation of fragility and resistance to modification and
change [8,9]. It is usually challenging to wholesale identify
the functional roles of any one amino acid, or to discern
which specific amino acids support a given function. Evolutio-
narily naive, de novo designed proteins can eliminate this
problem and provide a simple framework on which to build
function [10,11]. Ultimately, a protein is designed and con-
structed in which the roles of each individual amino acid are
more easily determined and controlled, and a more tractable
design process can thus be implemented.
Given the relative simplicity of designing helical peptides
and small helical bundle proteins, there are now many
examples of functional de novo designed proteins whose
scaffolds are constructed from alpha helices [11–15]. The
design principles for assembling helices are elementary: two
turns of an alpha helix can be formed by a heptad of amino
acids with helical-forming propensities (e.g. alanine, leucine,
glutamic acid), and repeating heptads of such residues will
extend the helix length as required [16]. To form larger oligo-
meric helical assemblies such as unlinked coiled coils, a
defined hydrophobic/hydrophilic periodicity is imprinted onthe heptads, dictating the size and orientation of the hydro-
phobic face, which in turn defines the oligomeric state of the
assembled peptides [17]. These coiled coils are often used in
de novo protein design and consist of bundles of two or
more helices that form a rope-like superhelical structure with
well-defined, interhelical knobs-into-holes packing [18–20].
The folding of coiled coils, and soluble proteins in general, is
driven by the favourable entropy change when water is
expelled from the interior of the folding protein [16,21].
Simple design principles similar to those employed in coiled-
coil heptad repeat patterns can also be used to construct
elementary 4-helix bundles that form discrete and stable
scaffolds that do not necessarily conform to coiled-coil struc-
tural parameters [16,22]. Most published de novo coiled coils
are parallel with respect to each other, and because their
N-termini are co-located, it is not possible to genetically loop
them together with short peptide sequences for expression as
a single-chain protein. However, in designs with helices that
assemble in an antiparallel manner, the helices can be linked
through simple loops containing residues with low helical-
forming propensities, such as glycine and serine [22,23].
Therefore, in these cases, a single-chain helical bundle can be
genetically encoded that not only facilitates in vivo protein
expression, but also allows the cross-bundle sequence
symmetry to be broken [23,24].
Even within a simple a-helix bundle, protein backbones
can have highly variable geometry in which each amino acid
can adopt many different side chain conformations. To
remedy this, recent research by the Baker group focused on
the design of protein interfaces with regular networks of
hydrogen bonds that specifically interact in a modular way,
similar to the base-pairing of DNA [25]. The simplicity of
a-helix bundle proteins is in many ways an advantage over
more complex structures. However, the design of larger struc-
tures, including those that involve b-sheets, may allow us to
access a wide range of functional capabilities. Existing de
novo protein designs form a diverse range of structures,
some of which are shown in figure 1.
The use of repeat sequences in protein design brings the
advantage of modularity and allows the construction of
larger, more complex scaffolds. Repeat proteins are prevalent
in Nature, and present attractive targets for protein design
[32]. For example, repeat five-residue (RFR) beta-solenoids
can tolerate substantial variations including mutations to the
loop regions that link together the individual beta-helix sub-
units [30]. To capitalize on the potential of these versatile
scaffolds, MacDonald et al. have developed computational
methods which were used to calculate de novo backbones
without using existing sequences of natural proteins [33–35].
The authors then created a set of genetically encodable, de
novo RFR-fold proteins with variable loops, and even whole
protein insertions in the loop regions [30] (figure 1e).
The TIM-barrel fold is possibly the most prevalent protein
topology found in natural enzymes, comprising eight a-helices
surrounding eight b-strands in a closed toroid [36]. Despite the
structural similarity of TIM-barrel enzymes, there is very little
sequence conservation across the many superfamilies that
adopt this topology [31,37,38]. While the TIM-barrel structure
appears complex, there is much interest in the design of this
topology de novo, owing to the functional diversity that
might be tangibly available to the designer. With recent
advances in computational protein design, the Baker group
has created a series of genetically encodable TIM-barrel
(a) (b)
(d)
(e)
( f )
(c)
Figure 1. The diversity of de novo designed protein structures. (a) Pizza variant, nvPizza2-S16H58, which coordinates a CdCl2 nanocrystal [26]. PDB: 5CHB. (b) De
novo designed reaction centre with heme B, synthetic Zn porphyrin and Zn(II) cations [27]. PDB: 5VJS. (c) Catalytic helical barrel, CC-Hept-I18C-L22H-I25E. Catalytic
triad residues are shown [28]. PDB: 5EZC. (d ) DFsc-Zn(II)2 used by Ulas et al. [29] for semiquinone radical stabilization. PDB: 2LFD. (e) Designed beta solenoid
proteins, SynRFR24.1 (red, PDB: 4YC5) and SynRFR24.t1428 (blue, PDB: 5DNS) [30]. ( f ) sTIM-11 [31]. PDB: 5BVL.
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reveal excellent structural fidelity to the original design. For
simplicity, the group aimed to design a structure with fourfold
symmetry, the maximum possible in this design. sTim-11
features four repeating motifs forming a structure which is
thermostable and reversibly folds after denaturation by
guanidinium chloride and temperature, providing a unique
structure for the precise placement of catalytic amino acids [31].
While the vast majority of designed proteins are soluble,
natural membrane proteins have an array of functions that
are worth replicating in de novo designed proteins, including
receptors, transport in and out of the cell, and roles in photo-
synthesis. However, the design of de novo membrane protein
scaffolds is hindered by the relatively small proportion of
solved membrane protein structures compared with soluble
proteins. In contrast to soluble proteins, designing a mem-
brane protein that assembles, localizes and functions as
intended is significantly more challenging. While the basic
design principles for de novo designed membrane proteins
are well established [39], in practice it is often the case that
the protein is incorporated into inclusion bodies [40] (which
is not ideal for in vivo function), or that their low yields [41]
and poor solubility can complicate downstream study.
Despite these difficulties, there have been significant
advances in de novo membrane protein design in recent
years, and achieving full, functional, biocompatibility is in
sight. Many de novo membrane protein designs are made via
peptide synthesis (see §4.5 De novo designed membrane
pores) [13], although amphiphilic maquettes can be expressed
in Escherichia coli and human embryonic kidney cells (see §4.2
Light-responsive artificial proteins) [40]. Recent research by
the Baker group has led to the design of de novo multipass
membrane proteins that locate to the membrane of E. coli and
human kidney cells, with crystal structures revealing fidelity
to the intended design [42].For a review of de novo designed protein structures see
Huang et al. [1]. Polymeric de novo peptides, such as the cat-
alytic beta amyloids designed by the Korendovych group, are
probably incompatible with the cell and therefore beyond the
remit of this review; for a review on this topic and other
catalytic peptide assemblies, see [43].
Function can be incorporated into a de novo protein design
through the use of cofactors; however, designing a highly
specific cofactor-binding site is not always straightforward.
Amino acid side chains can directly coordinate metal ions [44],
but when the metal ion is part of a larger structure, such as
heme, or in the case of other bulky molecules such as flavin,
the situation becomes more complex. While basic design prin-
ciples have been uncovered, progress in this area has been
slow. Research by the Koder andNoy groups involved the scan-
ning of databases of natural proteins to identify consensus
sequences and geometric properties for heme and chlorophyll-
binding sites using histidine residues [45,46]. While there are
computational methods in place for the design of cofactor-
binding sites (for metal-binding sites, see [44]), further progress
is required. Furthermore, when trying to replicate the function
of, for example, light-harvesting proteins which bind multiple
interacting cofactors, the situation becomes more complicated
still.Not onlymust the cofactors be specificallybound, in the cor-
rect orientations with the correct properties, but also their
interactions and properties must be tuned.
3. Fully biocompatible de novo designed
proteins
3.1. Life-sustaining functions
The Hecht group has explored whether proteins with
life-sustaining properties can spontaneously arise from combi-
natorial libraries of de novo designed proteins. These libraries
(a) (b) (c)
(d)
pNPA + H2O
pNP + acetate
(e)
2H2O2
2H2O + O2
ABTS
H2O2
ABTS•+
CO2 + H2O
HCO3– + H+
FeEnt
trimer
dimer monomer
Figure 2. A selection of catalytic de novo proteins. (a) Representation of the structure of a de novo protein which performs carbonic anhydrase activity. The solution
nuclear magnetic resonance structure of the a3D scaffold (PDB: 2A3D [53]), was modified to bind zinc (grey) and hydrate CO2 [54]. (b) Molecular dynamics
simulation model of C45, which can catalyse the oxidation of a range of small molecules, including 2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) [12]. (c) The de novo protein Dft2 was modified to bind manganese and perform catalase activity [55,56]. The crystal structure shown is that of the variant,
P0 (PDB: 5C39); variants with two and three manganese-binding sites exhibit higher activity. (d ) A 4-helix bundle library protein, Syn-F4, which performs enan-
tioselective hydrolysis of ferric enterobactin (FeEnt) [57]. As no structure is available of this protein, the structure shown is a representative 4-helix bindle from the
Hecht lab (PDB: 2JUA). (e) Crystal structure of the heptameric coiled-coil CC-Hept-I18C-L22H-I25E with hydrolase activity towards p-nitrophenyl acetate (pNPA).
Catalytic triad residues are shown. (PDB: 5EZC) [28].
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acids are considered as either polar or non-polar in a repeating
pattern, ensuring the resulting proteins were folded into stable,
discrete 3D structures [22,47]. The libraries were screened
for function through expression in various E. coli auxotroph
strains. Despite the stochastic nature of their sequence selec-
tion, several de novo proteins were capable of rescuing
specific knockout strains [48]. Some of these de novo sequences
have been demonstrated to act on gene regulation [49], in one
case allowing the cells to grow on toxic levels of copper [50].
One particular de novo protein, SynGltA, could rescue a citrate
synthase gene deletion mutant unable to catalyse the first reac-
tion of the tricarboxylic acid cycle. It was found that SynGltA
does not reproduce the catalytic activity of citrate synthase,
but instead upregulates a pathway which includes the pro-
miscuous enzyme methylcitrate synthase, producing
sufficient citrate to rescue growth [51]. This highlights the
potential roles de novo proteins might have in ‘rewiring’
gene pathways and metabolism in auxotrophs [51]. In
addition, a de novo catalytic protein, Syn-F4, has been devel-
oped from the library protein, Syn-IF. Syn-IF rescued two
different E. coli auxotroph strains, but did not appear to have
a catalytic role [52]. Following random mutagenesis and selec-
tion of protein variants that could more rapidly rescue the
auxotroph strain, the variant Syn-F4 was found to havecatalytic activity in vivo, namely the enantioselective hydrolysis
of ferric enterobactin (figure 2d) [57].3.2. Therapeutic functions
Man-made biocompatible entities offer opportunities for
designing therapeutic and diagnostic agents to combat disease,
an avenue the Baker group has explored [58–61]. Mimics of
pro-apoptotic proteins have been used as treatments against
diseases in which apoptosis is dysregulated, such as cancer.
One such approach is to mimic proteins that can inhibit,
through binding, BCL2 family pro-survival proteins that are
expressed in many cancers [60]. Members of this family have
very high sequence homology and structures, so specific
BCL2 binding is a challenge [60]. The Baker group has created
de novo proteins which bind to the BH3 binding groove of cer-
tain pro-survival proteins. Initially, a 3-helix bundle protein,
BINDI, was designed as an inhibitor of BHRF1, an Epstein–
Barr BCL2 homologue [61]. This scaffold was subsequently
modified to produce variants that could each bind one of the
six human pro-survival BCL2 family proteins (figure 3a), and
can be expressed in human cancer cell lines [60]. Rosetta
Monte Carlo sequence design was used to design the proteins,
which have three helices, onewith a central BH3motif. The two
remaining helices were designed to aid specificity and stability.
(a)
(b)
Figure 3. Crystal structures of de novo inhibitors binding to their targets.
Crystal structures of inhibitor complexes. (a) Inhibitor peptide aMCL1 (red)
binds the human BCL2 homologue, Mcl-1 (blue), with picomolar affinity
[60]. PDB: 5JSB. (b) Inhibitor peptide HB1.6928.2.3 (red), which can bind
influenza haemagglutinin [59]. PDB: 5VLI.
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proteins that differ in sequence between family members. Fol-
lowing computational design, two of the designed proteins
had high specificity and affinity for their targets, the remaining
four provided good starting targets for in vitro optimization.
Thus, these de novo proteins form a set of molecular probes
which can be used for various purposes, including determin-
ing which of the BCL2 proteins are involved in individual
cancers, and aiding understanding of the mechanisms of
mitochondrial apoptotic pathways [60].
The development of increasingly higher-throughput and
computational methods has been a great aid to the field of de
novo protein design, particularly when it comes to designing
therapeutics [62]. In a recent study, the Baker group has devel-
oped a high-throughput computational method using Rosetta
to design small protein binders of specific therapeutic targets,
in this case influenza A H1 haemagglutinin (figure 3b) and
botulinum neurotoxin B [59]. This method allowed the simul-
taneous study of thousands of small protein designs, in
which target binding and protein folding were characterized.
Of the 22 600 starting proteins, more than 10% exhibited
high-affinity binding to their targets; one protein was effective
against influenza infection in mice, even when administered
post-exposure. The proteins function in a similar way to neutra-
lizing antibodies, which bind to and neutralize the activity of
the target infectious agent or antigen, often preventing its
entrance into the cell. The designs are highly specific, stable
(including thermostable) and do not provoke an immune
response. Although these approximately 40 residue proteins
are genetically encodable, they can also be chemically syn-
thesized, presenting the opportunity of chemical modification
to expand their function. This high-throughput method is a
promising approach to the production of new therapeutics
and diagnostic tools for a wide range of targets [59].
There is much interest in the development of protein cages,
both natural and artificial, for the delivery of therapeutic mol-
ecules [63], for example by mimicking the function of a virus.
Synthetic nucleocapsids designed by the Baker group can be
fully assembled with their mRNA genome in E. coli cells and,following injection, persist in the circulation of mice for several
hours [64]. Computationally designed combinatorial libraries
were produced and subjected to rounds of directed evolution
to select for certain properties common to natural viruses: a
well-packaged genome, resistance to nucleases and persistence
in in vivo blood circulation. These nucleocapsids provide a tai-
lorable platform for future applications such as therapeutic
purposes, while minimizing the complexity found in naturally
evolved viruses.
3.3. Interaction of de novo proteins with cellular
machineries in vivo
To be fully biocompatible, a de novo protein must not only be
expressed in vivo, but also interact productively with natural
cellular machineries, while undesirable interactions are mini-
mized. The functionalities of natural systems may be
harnessed, for example, by transporting man-designed
elements to the desired location within the cell. In recent
research the E. coli twin-arginine translocation (TAT) appar-
atus, whose quality control mechanism will only allow the
export of fully folded proteins across the cytoplasmic mem-
brane, could ‘read’ the folding state of a completely artificial
heme-binding protein and translocate it to the periplasm [65].
While the bacterial Sec system has been proved capable of
transporting de novo proteins in an unfolded state [24], the
TAT system may be able to transport other de novo proteins
that must fold in the cytoplasm prior to translocation.
Beyond transport, there are other cellular processes that may
be exploited for themodification of de novo designed proteins,
such as the rich diversity of natural post-translational
modifications.
Cells can selectively insert cofactors, for example, using
accessory proteins and enzymes in what can be quite complex,
multistep pathways. Amino acids from the polypeptide back-
bone may be modified to produce in situ cofactors, such as
the covalently attached quinones (e.g. the topaquinone cofactor
found in natural copper amine oxidases [66]), which are often
formed through the modification of tyrosine or tryptophan.
Other modifications include catalytic activation or suppression
through phosphorylation, and glycosylation, in which carbo-
hydrate is covalently attached to the protein to aid stability
and modulate activity.
In recent research, the Anderson group has designed and
characterized an artificial heme C-containing oxidoreductase,
C45, which makes use of the native E. coli cytochrome c matu-
ration (Ccm) machinery to assemble the protein in its active
form in vivo [12]. The natural oxidoreductases are a functionally
diverse superfamily of enzymes, performing a plethora of
chemical transformations, and there has been much interest
in replicating and exploiting their functions through de novo
protein design [14,67,68]. Owing to their catalytic power and
potential utility in chemical synthesis and biotechnology,
there has been particular interest in the oxygenases and peroxi-
dases, catalysing the controlled insertion of oxygen into
carbon–hydrogen bonds and the coupled oxidation of small
molecules/reduction of hydrogen peroxide, respectively.
Within these enzyme classes, many contain catalytically versa-
tile heme cofactors that, despite the wide range of chemistries
displayed by heme-containing enzymes, use essentially the
same reactive intermediates to facilitate the diverse array of
chemical transformations [69]. While artificial peroxidases
have been developed [70,71], heme-containing oxygenases
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non-covalently incorporated into proteins that are expressed
in vivo [72] and it is possible to build a simple heme-binding
site within a de novo protein scaffold using histidine residues
to coordinate the heme iron [67]. However, covalently append-
ing heme to the protein backbone ensures secure and
practically irreversible attachment of the cofactor, and can
facilitate the design of more sophisticated de novo assemblies
[24]. C45 has arisen from the iterative improvement of
oxygen-binding c-type cytochrome maquettes which contain
a CXXCH motif on the protein backbone for heme C insertion
by the cytochrome c maturation (Ccm) apparatus [12,24,68].
Unlike these catalytically inactive maquettes with bis-histidine
heme ligation, C45 contains a monohistidine ligated heme,
allowing molecules such as hydrogen peroxide to bind in the
vacant heme coordinate site and become activated towards
simple substrate oxidation reactions. C45 is catalytically pro-
miscuous and can oxidize a range of small molecules
(figure 2b) [12].With regard to catalytic efficiency, C45matches
the activity of natural peroxidases against certain substrates. As
C45 is produced in its functional form in E. coli, it can probably
perform this type of peroxidase catalysis in vivo.4. De novo designed proteins: in vitro assembly
and function
Many de novo proteins can be genetically encoded as single-
chain proteins that can be expressed by living cells [23,24].
However, the designs may often incorporate functional
elements that are not synthesized or constructed by the host
cell and must currently be added in vitro [23]. Therefore,
many genetically encodable artificial proteins are expressed
in E. coli and subsequently purified for further assembly,
study and analysis [73,74]. Future challenges include the cre-
ation of new biosynthetic pathways to synthesize novel
cofactors in cells, and the design of specific binding sites with
high affinity for the intended cofactor. To date, de novo pro-
teins have been designed to mimic a variety of natural
protein functions; advances in the last few years are discussed
below, with perspectives on biocompatibility.
4.1. Artificial enzymes
In Nature, protein catalytic function is often complex, with
many factors working in concert to allow efficient chemistry
and to ensure the reaction is thermodynamically favourable.
These factors may include diffusion of the substrate and pro-
duct in and out of the active site, quantum tunnelling effects,
transition state stabilization, specificity and concerted protein
dynamics [75–79]. In many cases, the precise alignment and
proximity of a substrate molecule and active-site amino acid
side chains is important [80,81]. Imparting of catalytic function
onto a de novo scaffold can therefore be a challenge. There are
many examples of catalytic de novo proteins and peptides, and
these are reviewed in Zozulia et al. [43], some of which are
shown in figure 2. A successful route to achieving catalysis
has included the use of metal cofactors to perform chemistry,
for example the aforementioned heme C-containing maquette,
C45, which performs efficient catalysis without a highly
specific substrate binding site [12,82] (figure 2b). However, in
many cases it has been necessary to incorporate the cofactors
in vitro, and further research and development is required to
enable full functional assembly in vivo.Asmost natural diiron-containing enzymes contain at their
core a 4-helix bundle that binds the two iron ions necessary
for their diverse and powerful enzymatic functions, these
enzymes were early targets of de novo protein design [83].
The natural enzymes catalyse a variety of substrate oxidations
and oxygenations, including the thermodynamically challen-
ging hydroxylation of methane [84]. Within the iron-binding
core of the natural enzymes, the iron ions are generally coordi-
nated by two histidine and four carboxylate residues [85]. The
DeGrado grouphas performedmuchworkon its due ferri (DF)
de novo proteins, whose simplicity has provided significant
insight into the natural non-heme diiron enzymes; for a
review of artificial diiron-oxo proteins of the DF family, see
Chino et al. [85]. Iterative design processes on the single-
chain protein, DFsc, have produced variants with increased
solvent and substrate accessibility, and modified reactivity—
from hydroquinone oxidation to selective N-hydroxylation of
arylamines [86]. The incorporation of a third ligating histidine
residue to the variant G4DFsc altered the enzyme’s function,
mimicking the active site of p-aminobenzoate N-oxygenase, a
natural diiron protein [86]. The modified protein gains
oxygenase activity towards p-anisidine, while 4-aminophenol
oxidation is disfavoured [86]. As the coordination of one iron
site is saturated, a slower substrate binding rate is observed,
inhibiting oxidase reactivity [87,88]. While both G4DFsc and
3His-G4DFsc bind p-anisidine near the biferrous site, the geo-
metry of this site is differentially perturbed in such a way as
to influence reactivity. While these proteins are expressed in
E. coli, they are reconstituted with iron in vitro, and would
probably require a significant increase in iron affinity to
promote in vivo assembly and activity.
Other metal ions have been effectively used as catalytic
cofactors in de novo designed proteins. The Pecoraro group
has designed a carbonic anhydrase (CA) mimic, with a zinc-
containing active site analogous to that of CA II, but in a
3-stranded a-helical coiled coil as opposed to the b-sheets
found in CA II. While the efficiency of CO2 hydration is
within two orders of magnitude of CA II, it is a parallel assem-
bly whose symmetry hinders improvements and is not
manufacturable in vivo [89]. In a more recent study, the Pecor-
aro group modified an existing single-chain DeGrado scaffold,
a3D [53,90], to bind zinc and hydrate CO2 (figure 2a) [54].
Although the catalytic efficiency is 1400-fold less than that of
CA II and 11-fold less than that of CA III, the simple scaffold
and iterative design strategy will facilitate the design of
improved function. The protein can be expressed in E. coli,
laying the groundwork for future design of in vivo activity
[54]. a3D has been modified to bind various other metal ions
to perform functions other than catalysis, such as copper [91]
(see §4.3 Designed electron transport proteins) and heavy
metals [92] (see §4.4 Artificial metal-sequestering proteins).
Many natural proteins contain manganese cofactors,
which have a wide variety of functions, notably the evolution
of molecular oxygen. Allen and colleagues have altered a
DeGrado DF protein, Df2t, to produce a series of four helix
bundle proteins, made up of two monomers, with dinuclear
manganese (Mn) binding sites, analogous to that found in
Mn-catalase (figure 2c) [55,56]. These proteins exhibit catalase
activity, converting hydrogen peroxide into molecular
oxygen. Variants, ‘P1’ and ‘P3’, with three metal-binding
sites exhibited higher activity than those with fewer binding
sites, ‘P0’ (one site) and ‘P2’ (two sites). The apo-proteins
were purified from E. coli, and the Mn cofactors were
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proteins can also transfer electrons to bacterial reaction centres
(RCs), discussed in §4.2 Light-responsive artificial proteins.
Catalytic function has also been integrated into de novo
designed scaffolds without the use of cofactors. Burton et al.
[28] reported a de novo helical barrel with active sites that
mimic those of natural cysteine/serine hydrolases, in which
amino acid side chains alone catalyse the reaction (figure 2e).
This structure comprises seven helices forming an 8 A˚ diameter
channel, with each helix featuring a cysteine–histidine–gluta-
mic acid catalytic triad in the barrel lumen, resulting in a total
of seven catalytic triads in the fully assembled protein. A combi-
nation of rational design and iterative strategies was used in
which the design was fully characterized with each additional
mutation. Although there have been other de novo protein
hydrolase designs containing Zn2þ with higher catalytic effi-
ciency [93,94], this protein forms a unique structure with a
highly mutatable de novo scaffold, and sequential rounds of
directed evolution may aid further enhancement of its catalytic
ability.While this proteinwas produced using peptide synthesis
and is a parallel assembly and not a single-chain construct and
therefore cannot be constructed in vivo, it is a good recent
example of how catalysis may be performed in a de novo
designed protein without the requirement for cofactors.4.1.1. Steps towards catalysis in de novo designed proteins
With the exception of a few notable examples, most de novo
enzymes fall short of the catalytic efficiencies exhibited by
natural enzymes. A richer understanding of how natural
enzymes work and how to import these functions into de
novo designed elements may enable us to perform more com-
plex or tuneable reactions. This section briefly discusses some
current ways in which de novo design is being used to under-
stand some features of natural enzyme catalysis with the hope
that we may be able to use this new knowledge to create
improved artificial protein catalysts.
Enzymes can stabilize high-energy intermediates, and
some make use of radicals, which must be controlled to
avoid damage to the enzyme. It is not well understood how
natural proteins can stabilize these unstable species, and
Tommos and colleagues have used de novo proteins as
models to study the stabilization of amino acid and mercapto-
phenol radicals [95–97]. The DeGrado group has used rational
protein design to stabilize ortho-semiquinones, common rad-
ical intermediates found in natural catalysis and redox
processes [29]. In this study, a 4-helix bundle protein, DFsc,
was used to bind Zn(II), to which the semiquinone was stabil-
ized through binding (figure 1d). The location of the Zn(II) in
the hydrophobic cleft of the protein excludes the bound semi-
quinone from the bulk water. At room temperature and in
aqueous medium, binding of the semiquinone radical, SQ†,
was favoured over binding of the more stable QH2 and Q
forms. The design principles used here, in which the radical
is stabilized through metal–ligand interactions and burial of
hydrophobic groups, may allow us to design artificial enzymes
that can perform more complex chemistry [29].
The rate of an enzymatic reaction in a de novo designed
active site is often limited by imperfect geometry. Therefore,
the ability to customize a ligand-binding pocket towards
high specificity is an advantage. The Baker group investigated
using beta sheets to custom-design backbones for binding a
specific ligand [98]. Furthermore, in natural proteins, aminoacids far (10–20 A˚) from the active site can contribute to
ligand-binding geometry, and DeGrado and colleagues [99]
have designed a de novo protein, PS1, with this in mind. PS1
was designed to mimic natural proteins with apolar folded
cores which support cofactor-binding regions. Prior to cofactor
binding, the binding region is flexible relative to the tightly
packed core. On binding the cofactor, the entire protein is
tightly packed and stabilized. PS1 is faithful to the design to
sub-A˚ level, and binds a non-natural porphyrin with high
thermostability. The success of this approach is promising for
the design of improved catalytic de novo proteins, and their
structural characterization [99].4.2. Light-responsive artificial proteins
Natural photosynthesis is a highly organized process using
pigment–protein complexes to harvest light energy, which is
ultimately used to power ATP synthesis. There are many
components in natural photosynthetic pathways working
synergistically to ensure efficiency and productivity while
maintaining the ability to quickly adapt to changing envi-
ronmental conditions. Although complex, photosynthesis
provides a rich source of natural engineering principles from
which to draw inspiration for the design of functional de
novo proteins. Ultimately, the de novo design of photosyn-
thetic proteins may allow the construction of customizable,
modular photosynthetic pathways that are adaptable to and
stable within the desired conditions, to light-power the
production of valuable products.
Many of the key proteins involved in photosynthesis are
membrane proteins. Therefore, efforts have been made to
design artificial transmembrane proteins that can emulate the
functions of their natural counterparts. Artificial membrane
proteins can bind a variety of cofactors such as heme, Zn-
and Ni-bacteriochlorophylls, and synthetic tetrapyrroles
[100–102]. Amphiphilic maquettes consist of two distinct con-
tinuous hydrophilic and lipophilic domains, the latter being of
a suitable length to span a lipid bilayer [100,101]. Until recently,
amphiphilic maquettes were constructed from self-associating,
unlinked helical peptides; however, to break symmetry and
therefore increase mutability, a single-chain amphiphilic
maquette has been designed [40]. This maquette is expressed
in E. coli, and, in vitro, can bind multiple b-type hemes and
photoactive Zn protoporphyrin IXs, potentially capable of sup-
porting a light-activatable intra-protein electron transfer (ET)
chain. Although this protein forms inclusion bodies when
expressed in E. coli, the authors ultimately aim to express and
assemble these proteins in vivo with natural cofactors [40].
Despite advances in designing de novo membrane pro-
teins, it remains simpler to design and work with soluble
proteins. Membrane proteins require solubilization with deter-
gents, particular design principles for folding and membrane
insertion [103] and often more complex purification protocols
than soluble proteins. There is therefore increasing interest in
creating water-soluble proteins that perform the function of
proteins found in natural photosynthesis, recent examples of
which are detailed below.
Photosynthetic organisms tend to occupy particular
spectral niches depending on the absorbance of their bio-
synthesized pigments, and therefore do not exploit the full
range of the available solar spectrum [104]. It would thus be
exceptionally beneficial to design artificial light-harvesting
pathways that could use a greater range of solar energy [105],
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artificial proteins that selectively bind natural or artificial
light-harvesting molecules. Maquettes have been designed to
bind light-active chlorins [106,107]: these de novo proteins
afford the protein engineer a greater freedom for design than
natural light-harvesting proteins, and may be customized to
absorb specific wavelengths of light. The hydrophobic nature
of many photoactive tetrapyrroles, both natural and synthetic,
can render binding to artificial proteins problematic. Natural
proteins often use accessory proteins to obfuscate this problem,
but a less complex approach would be beneficial to the assem-
bly of de novo proteins. Successful methods in incorporating
such hydrophobic molecules into soluble proteins have
included the use of detergents [108] or water-in-oil emulsions
[109], although other strategies would need to be developed
to achieve this in vivo. One approach used in previous work
regarding the incorporation of chlorophyll (Chl) and bacterio-
chlorophyll (BChl) into soluble de novo proteins involved the
removal of their hydrophobic tails to improve solubility and
prevent aggregation [106,107,110]. However, to best make
use of the wide range of synthetic and natural light-harvesting
pigments (e.g. synthetic chorins and bacteriochlorins) available
for use in synthetic systems and whose solubility is variable,
we must understand how to effectively incorporate them into
the desired protein scaffold without the need to modify the
properties of the molecule. Kodali et al. [111] have recently
demonstrated how to strike a balance between the hydro-
phobic and hydrophilic nature of the cofactors by producing
a soluble light-harvesting maquette which partitions the non-
polar region of amphiphilic tetrapyrroles into the interior of
the 4-helix bundle, while the polar portion is exposed to the
aqueous environment. In this work, the authors used Zn tetra-
phenyl porphyrins and Zn chlorins whose solubility in
different environments was altered through substitutions at
the meso-position of the tetrapyrrole ring. These porphyrins
were then titrated into a maquette with ligating histidines to
determine the optimum cofactor characteristics for binding.
Furthermore, within the same maquette, it is possible to
include ligating histidines with different binding affinities
to incorporate more than one cofactor type into the same
scaffold [111].
To achieve biocompatibility, artificial components must
work in symbiosis with natural proteins, and functional inter-
actions between man-made and natural proteins may allow
us to access functions beyond the current capabilities of de
novo protein design alone. One approach has been to create
natural–artificial protein chimeras. The Noy group fused a
domain of a natural phycobiliprotein with a de novo 4-helix
bundle binding a light-active zinc porphyrin or bacteriochlorin
[112]. The direction of Fo¨rster resonance energy transfer (FRET)
between the fusion domains could be altered depending on the
particular pigments bound. Such directionality is highly impor-
tant in natural light-harvesting proteins, ensuring light energy
is captured efficiently. In recent research, Mancini et al. [113]
have created a light-harvesting/energy transfer fusion between
a natural bilin-binding protein, CpcA and a 4-helix maquette
featuring two photoactive tetrapyrrole-binding sites. The first
cofactor-binding site of the maquette can ligate Zn-tetrapyr-
roles through a histidine residue in the hydrophobic interior
of the maquette. The hydrophobic regions of the Zn-chlorin
are buried, while maintaining close proximity to the phycobili-
protein for efficient FRET. The second binding site within the
maquette is a cysteine residue which facilitates covalentattachment of a synthetic maleimide-functionalized bacterio-
chlorin, which buries itself in the maquette interior. The
entire construct, fully assembled with cofactors, covers a large
portion of the UV and visible absorbance spectrum. It can cap-
ture light energy and perform multistep excitation energy
transfer from the natural bilin-binding protein to the tetra-
pyrroles of the synthetic protein. These studies demonstrate
how natural and synthetic proteins may ‘work together’ for
multistep excitation energy transfer, and present tailorable
light-harvesting properties due to the option to incorporate
different cofactors that absorb different wavelengths of light.
Building on this work, de novo proteins with more complex
systems of light-active cofactors may be created to more closely
mimic natural light-harvesting proteins which can possess a
higher number of bound pigments per polypeptide chain.
Though these artificial proteins can be genetically encoded,
the functional photoactive complexes are currently assembled
in vitro. To achieve full biocompatibility, these proteins must
bind their photoactive prosthetic group in vivo; this can be
achieved through the specific binding of photoactivemolecules
either endogenous to the cell, supplemented in culture or
produced from a recombinantly expressed biosynthetic
pathway in vivo. Mancini et al. [113] report that chlorins
native to the photosynthetic cyanobacterium Synechocystis sp.
PCC603 bind maquettes expressed in vivo. Phycobilins can
also be attached onto maquette cysteine residues in E. coli
when co-expressed with bilin synthases and lyases [113].
Beyond light harvesting, there are many downstream
photosynthetic functions that could be imprinted onto artifi-
cial components, including, for example, de novo designed
RCs for biomimetic, photoinduced charge separation. Here,
the light-harvested electronic excitation energy is converted
into the release of electrons into an electron transport chain.
Photosystem II obtains these electrons through the photolysis
of water, and a prototype PSII maquette is in development
by Dutton and colleagues [15]. De novo designed electron
transport proteins are discussed in §4.3.
During photosynthesis photoprotection is required. In the
presence of high or fluctuating light conditions, Chl and
BChls can form triplet states capable of donating their energy
to O2, producing singlet oxygen. Photosynthetic organisms
have evolved various strategies to prevent singlet oxygen
damage, including non-photochemical quenching (NPQ)—
the dissipation of excess energy as heat, and the involvement
of pigments such as carotenoids which can directly quench
the singlet oxygen state and the triplet B/Chl state, followed
by NPQ [114]. An artificial light-harvesting system must be
able to perform similar protective mechanisms. The maquette,
HP7, boundwith two zinc-substitutedChl derivatives, can effi-
ciently undergo relaxation through NPQ when the pair is
photoexcited [106]. The protein environment surrounding the
BChl pair can control the fate of the excitation, so the maquette
can be adapted for light harvesting, leading to energy transfer,
for charge separation or for energy dissipation [115]. Although
this designed protein is not a single chain and therefore prob-
ably cannot be constructed in vivo, the design principles
learned here may be adapted for a biocompatible component.
In addition to roles in photosynthesis, light-sensing proteins
can perform other functions. Cryptochrome proteins contain a
flavin adenine dinucleotide (FAD) cofactor that forms a radical
pair (RP)when exposed to blue light. These proteins are respon-
sible for a variety of functions, including growth towards light
in plants, the control of plant development and the regulation
rsif.royalsocietypublishing.org
J.R.Soc.Interface
1
9
 on September 14, 2018http://rsif.royalsocietypublishing.org/Downloaded from of circadian rhythms. Cryptochromes are also thought to be
involved in magnetic sensing [116]. Interconversion of the sing-
let and triplet states of the RP is sensed in terms of its timing and
extent to achievemagnetosensitivity [117].A flavomaquette that
is capable of light-mediated magnetic field sensing has been
designed and constructed [74]. This maquette was created
to aid understanding of the properties required by natural pro-
teins to sense magnetic fields. The maquette does not bear any
resemblance to the natural chryptochrome fold but forms a
chryptochrome-like light-active RP that is magnetically sensi-
tive. As in natural chryptochromes, photoinduced ET from a
nearby tryptophan to the flavin results in formation of the RP.
The protein was expressed in and purified from E. coli, but the
flavin cofactor, 8-bromo-riboflavin,was covalently incorporated
in vitro. Natural cryptochromes contain a triad of tryptophans
that act as a light-activated electron transport chain, which the
authors aim to replicate in future designs. 5:201804724.3. Designed electron transport proteins
An area that has beenmuch explored in de novo protein design
is the creation of artificial ET proteins. These proteins could be
integrated with respiratory processes/complexes in vivo to
divert electrons directly towards the production of useful pro-
ducts or improving respiratory energy conversion in humans
in the case of disease or ageing [118], or could redress redox
imbalances caused as a result of metabolic engineering [119].
Theymay also have a role in photosynthesis; the previously dis-
cussed Mn-proteins designed by Allen and colleagues can
transfer electrons to natural bacterial RCs, subsequent to illumi-
nation—which induces the RC charge-separated state. This
process is analogous to the rapid reduction of RCs by natural
secondary electron donors, such as cytochrome c2. Modelling
results indicate that the artificial proteins bind the periplasmic
face of the RC in a manner similar to cytochrome c2 [55,56].
In Nature, proteins containing iron–sulfur clusters are
often involved in respiratory andphotosynthetic electron trans-
port chains. De novo ET proteins have been engineered to
incorporate [4Fe-4S] clusters [120]. In a recent example, a de
novo ferredoxin mimic was designed, which incorporates
two [4Fe-4S] clusters in a 3-helix scaffold [121]. In a subsequent
study mutants of this protein were produced to modulate
redox potential and stabilize [3Fe-4S] [122]. For the construc-
tion of synthetic ET chains, or for accessing more
sophisticated redox catalysis, this ability to tailor redox proper-
ties, such as potential anddirectionality, is an advantage. These
proteins are produced by peptide synthesis and are not single
chain; however, it is possible to incorporate an iron–sulfur
cluster into a single-chain scaffold [73]. See also Dizicheh
et al. [123] for a review of the incorporation of FeS clusters
into both natural and artificial scaffolds.
A rate-limiting step in inter-protein ET between the multi-
protein complexes of the respiratory chain is the transient
encounter between the redox partners so that they are within
a suitable distance for efficient ET [124]. Cytochrome c is a dif-
fusible protein of the mitochondrial electron transport chain
and it, along with many other natural proteins, uses comp-
lementary surface electrostatics to promote transient
interactions between it and its redox partners [125]. As
maquettes are highly tolerant to extensive changes in
their surface residues, they provide an ideal platform for
investigating the effect of differing electrostatic surface charac-
teristics. Fry et al. [118] have designed a genetically encodableheme-binding maquette that can reduce cytochrome c at
physiologically relevant (millisecond) rates. In this way, cyto-
chrome c may act in vivo as a mediator between the artificial
maquette and the natural redox partners of cytochrome c,
who either have a net negative charge or have negatively
charged surface regions. It therefore followed that themaquette
with a net negative charge was demonstrated to more rapidly
reduce cytochrome c than that with a net positive charge.
This work demonstrates that, for effective biological ET, a net
complementary charge is sufficient as opposed tomore specific
protein–protein binding interactions. In this case, it was not
necessary to design a specific docking site; however, it would
be advantageous to design de novo proteins that specifically
interact with natural proteins.
The Pecoraro group has sought to explore whether the
characteristics and properties of metals in natural proteins
can be retained when placing a metal-binding site in a de
novo designed protein with a different topology. Natural ET
cupredoxin, CuT1, proteins contain copper-binding centres
that are often found within a beta-barrel framework. The de
novo protein, a3D [53,90] (see §4.1 Artificial enzymes), was
modified to incorporate a copper-binding centre [91,126]. A
2HisCys(Met) metal-binding site was modelled within the
3-helix bundle, and the resulting protein can be purified from
E. coli. The spectroscopic properties of native cupredoxins
were not fully replicated in the designed protein; however,
the de novo protein is capable of intramolecular ET, and can
perform ET with a photosensitizer. In the future, the authors
aim to optimize the structure to improve its properties, includ-
ing ET efficiency, and to incorporate both an ET and a catalytic
site within the same scaffold to mimic natural enzymes such as
copper nitrate reductase. In recent research, the same grouphas
used the a3D scaffold to build in a rubredoxin site, containing
one iron, using a CXXC motif, with the same spectroscopic
characteristics as its natural counterpart despite the site being
in a different fold [127].
The ET components described above have the potential to
be integrated into systems in conjunction with man-made
oxidoreductases or natural proteins. This could mimic the
function of natural systems, or be used to create an assort-
ment of biomimetic components that can interact in ways
not observed in Nature.4.4. Artificial metal-sequestering proteins
Natural proteins may bind metal ions or compounds for pur-
poses other than catalysis, photosynthesis and ET. In Nature,
features such as teeth, bones and shells are created by biominer-
alization [128]; in many cases, proteins and enzymes are
involved in these processes [129]. These proteins are of interest
in many fields as the materials they deposit may have desirable
electric, optical and magnetic properties. To this end, a de novo
designed protein, Pizza, has been engineered to synthesize cad-
mium chloride nanocrystals. One Pizza variant, Pizza6, is a
computationally designed self-assembling de novo b-propeller
protein with sixfold symmetry and high thermostability, and
is expressed and purified from E. coli. [129]. A version of Pizza
was designed with histidine residues at the trimeric interfaces
(nvPizza2-S16H58; see figure 1a), with the intention that it
would only assemble in the presence of metal ions [26]. This
would inevitably increase stability of the protein complex but
also aiddisassemblybyexposure to chelators. Thedesigned sub-
units consist of two propeller domains per polypeptide which
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induces adimerizationof these trimers through the coordination
of a 19-atom cadmium chloride nanocrystal by the symmetri-
cally positioned histidine residues. Trimerization is observed
in the absence of cadmium chloride, probably through a water
molecule forming hydrogen bonds with the three histidine resi-
dues. The authors envisage introducing catalytic activity to the
structure, as awater-filled tunnel is formed on one face, reminis-
cent of the buried tunnels containing catalytic metal ions in the
active sites of catalase and superoxide dismutase.
Metalloregulatory proteins regulate ion flux and delivery
within the cell while limiting levels of potentially toxic heavy
metals. Pecoraro and colleagues [130] have created an artificial
3-helix bundle protein, a3DIV, that can bind Hg(II), Pb(II) and
Cd(II). a3DIV is a redesigned variant of the DeGrado protein
a3D and contains the triscysteine motif found in many metal-
loregulatory proteins. a3DIV is stable, with a more tightly
packed core than a3D, and heavy metal binding induces
further stability. The protein can be genetically encoded and
expressed in E. coli and has been structurally characterized
by nuclear magnetic resonance [92]. In a subsequent study, a
fourth cysteine residue was introduced at one of two different
sites in a3DIV to mimic the tetrathiolate binding site found in
CadC, a transcriptional repressor protein that regulates the
levels of intracellular Cd(II) [131]. As was identified with
CadC, the tetrathiolate site in the artificial protein coordinates
Cd(II) as a mixture of rapidly exchanging CdS3O and CdS4
species. Thus, the artificial metal binder acts as a model for
its natural counterparts.4.5. De novo designed membrane pores
Membranes provide a vital boundary between the cell and the
outside world, strictly controlling what goes in and out of
the cell. Natural membrane pores havemany functions, includ-
ing signalling and transport. Although providing selective
transport across the cell membrane without compromising
membrane integrity is a particular challenge, the capability of
creating de novo designed membrane pores is highly advan-
tageous, potentially facilitating the design of proteins tailored
to specific ‘cargo’ molecules, through pore size and sequence.
However, the design of de novo membrane protein scaffolds
is hindered by the relatively small proportion of solved
membrane protein structures compared with soluble proteins.
Currently, de novomembrane nanopores come inmany differ-
ent forms, with examples constructed from proteins, DNA and
organic materials [132].
A notable example of a de novo designedmembrane pore is
Rocker, a Zn2þ/Hþ antiporter, designed by the DeGrado lab-
oratory [13,133]. Rocker is a computationally designed
transporter protein which can transport Zn2þ or Co2þ ions,
but not Ca2þ, across membranes, with the concurrent antiport
of protons. The phospholipid bilayer of biological membranes
is impermeable to metal ions, and transporters are required to
transportmetal ions such as Zn2þ across themembrane. Rocker
was designed with the aim of emulating the alternating access
‘rocker-switch’ model by which many natural transporter pro-
teins are thought to operate, rocking between different states. It
is a membrane-spanning de novo designed 4-helix protein that
features two di-metal binding sites with negative cooperativity
of binding. As more than 100 protons are transported per Zn2þ
ion, Rocker’s efficiency does not match that of natural proteins;
however, it represents an example of how function can beachieved through a protein scaffold that is simple in compari-
son with its natural counterparts, with potential to engineer
additional features to improve the transport efficiency.
Moreover, although Rocker was produced through solid-
phase peptide synthesis, production of a genetically encoded
variant may be possible as the helices run antiparallel, facilitat-
ing a single-chain design. The fact that the protein can assemble
in micelles and phospholipid bilayers is a promising indica-
tion that similar de novo proteins may readily insert into
cell membranes.
Peptides that form pores inside membranes in acidic con-
ditions were recently designed by the DeGrado group [134].
The computationally designed 28-residue peptides consisting
of four 7-residue repeats are of sufficient length (42 A˚) to span
the cell membrane. The in vivo extracellular environment is at
a pH of 7.4, and at this pH the peptides are water soluble. As
the pH is lowered, the peptides bind discretely to membrane.
At pH 5.5, resembling the acidic conditions found within the
endosome or lysosome, the peptides assemble to form trans-
membrane pores. When the peptides were added to red
blood cells, miRNA and ATP were selectively released, but
not haemoglobin, while preserving membrane integrity.
With further research and understanding, the authors envi-
sage creating ‘selective membrane-permeating tools’ for a
variety of cargo.
Another approach to selectively breach the cell membrane
is to mimic the function of a virus, in which the encapsulated
DNA or RNA is delivered into a host cell. Noble et al. [135]
have created TecVir, a de novo design that forms a virus-
like topology from coiled-coil peptide helices, which can
transfer both RNA and DNA into human cells without cyto-
toxic effects. Each peptide helix was designed with one
hydrophobic face and two polar interfaces, which allow it
to interact with three identical neighbour helices; they pack
to form a shell and can be co-assembled with DNA or
RNA. Although TecVir is made in vitro through peptide syn-
thesis, the assembly shows biocompatibility as it can transfect
human dermal fibroblasts with a plasmid encoding eGFP
without appearing to disrupt cell morphology as it is taken
up by cells through endocytosis. Like the pore-forming pep-
tides above, TecVir is pH responsive; at acidic pH, TecVir
unfolds, allowing entry of the genetic cargo to the cytoplasm.5. Chemical mimics of protein function
It is not exclusively artificial proteins and peptides that can
mimic protein function. Some designed chemical constructs
have the potential to be biocompatible, and work with or in
cells. This section delineates two recently reported studies
in which molecules are used for transmitting signals across
membranes.
Natural G-protein-coupled receptor (GPCR) signalling
proteins are membrane bound. When a ligand signal is
bound, a conformational change is induced in the GPCR,
which initiates a signalling cascade within the cell. The Clay-
don group considered the minimal set of components
required to create a GPCR mimic and subsequently designed
a membrane-bound synthetic receptor (figure 4a) [136]. The
receptor binding site contains a Cu(II) ion, to which a carbox-
ylate ligand binds. This binding induces a conformational
change across the receptor, consisting of a helical foldamer
core derived from peptabiols, a fungal class of antibiotics.
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Figure 4. De novo transmembrane components for signalling. (a) A synthetic GPCR mimic [136]. The synthetic receptor consists of a ligand-binding pocket featuring
a cationic metal complex (red), an Aib oligomer (grey) and a pair of pyrene molecules attached to a chiral diamine ( purple and blue). This complex adopts one of
two mirror image conformational states on complexation with a chiral ligand. The binding of a chiral ligand (magenta) to one end of an Aib oligomer propagates its
conformational influence along the entire length. The signal is output by the conformationally responsive fluorophore ( purple and blue). Thus, the binding of the
cofactor perturbs the global conformation, which is reported by the fluorophore component. (b) A translocatable sensor [137] in which two head groups are coupled
to a steroid spacer (grey). The external sensor is a protonated morpholine (red or blue), while the second head group is a neutral pyridineoxime ‘pro catalyst’
(magenta or green). When the head groups are polar (red or green), they prefer to sit in the aqueous phase; when non-polar (blue or magenta), they prefer
to sit in the membrane. Binding of a zinc cofactor from within the vesicle pulls the pro-catalyst head group into the aqueous phase on the interior of the vesicle.
This allows the hydrolysis of the substrate within the vesicle, generating the output signal.
rsif.royalsocietypublishing.org
J.R.Soc.Interface
15:20180472
11
 on September 14, 2018http://rsif.royalsocietypublishing.org/Downloaded from Peptabiols can insert into the membrane bilayer and contain
the quaternary amino acid, a-aminoisobutyric acid (aib). Oli-
gomers of Aib have strong helical propensity, and decamers
are long enough to span the membrane bilayer. In solution
these oligomers switch between two different conformational
states, left- or right-handed screws, and the binding of chiral
ligands determines which of these states is favoured. At the
other end of the molecule is a fluorophore consisting of a
pair of pyrene molecules attached to a chiral diamine. This
fluorophore is sensitive to conformational change: mono-
meric pyrene has an emission at 378 nm, but in a certain
spatial arrangement a pair of pyrene fluorophores may emit
at 450 nm. Thus, the binding of the cofactor affects the confor-
mation of the whole receptor structure, which is reported by
the fluorophore component.
Another study focused on the transmission of a signal
using a switch localized in either the outer or inner leaves of
the membrane (figure 4b) [137]. Two head groups are coupled
to a steroid spacer; one of the head groups, a protonated mor-
pholine, is the external sensor and the other is a neutral
pyridineoxime ‘pro-catalyst’. When the sensor head group is
polar, it sits in the aqueous phase awaiting the chemical
signal, while the non-polar pro-catalyst sits in the membrane.
On binding a signal, the sensor head group becomes non-
polar, inducing translocation across the membrane. Binding
of a zinc cofactor from within the vesicle switches the pro-cat-
alyst head group to polar, thus moving it into the aqueous
vesicle interior. This activates the catalyst and allows the
hydrolysis of the substrate to a fluorescent product within the
vesicle. This signal transduction mechanism has been used to
trigger the release of cargo from a vesicle, which may aid the
development of drug delivery systems [138].
These artificial signal transducers must be assembled
in vitro; however, as they can function in vesicle lipid bilayers,
they may well be able to function in vivo, acting as an
interface between biological and synthetic systems.5.1. Making non-natural components biocompatible
While many chemical entities may have potential as biocom-
patible mimics of natural function, further research is
required to effectively interface between biological and
chemical elements to achieve full biocompatibility and
functionality under physiological conditions.
A step towards achieving full biocompatibility with or
within cells is to optimize the element’s function under phys-
iological conditions, and to work in partnership with natural
proteins. To take an example, while natural proteins do not
make use of precious metals for catalysis, these metals are
used in many industrial reactions. To function as part of an
artificial metalloenzyme requires strategies to aid their bio-
compatibility; biotin/streptavidin technology has been
exploited for this purpose. The Ward group described an arti-
ficial metalloenzyme which has a biotinylated organometallic
iridium catalyst anchored to an engineered streptavidin
protein scaffold [139]. The streptavidin has a C-terminal artifi-
cial activating tripeptide ligand which, on proteolytic
cleavage, then coordinates to themetal of the cofactor and acti-
vates the enzyme. In another study by the same group, an
organometallic catalyst is integrated with natural proteins as
part of an enzyme cascade to produce enantiopure amines
[140]. It is difficult to fully assemble such metalloenzymes
in vivo, in part due to the presence of inhibitors such as gluta-
thione in cells [141]. The Ward group reported that
compartmentalizationwithin cells can be an approach to over-
come this, as, for example, the periplasm contains a relative
lack of glutathione. An artificial metalloenzyme for olefin
metathesis (a reaction that does not occur in Nature) was
expressed with a periplasmic export tag. The protein
assembled in vivo in its functional form, and in vivo directed
evolution was used to optimize the protein. In this case, the
cofactor was biot-Ru, which is inactive until it is assembled
as the mature form of the metalloenzyme [142].
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There is still much progress to be made when it comes to fully
biocompatible functional de novo proteins, although there are
a few examples which fulfil these criteria [12,57,59,64]. With
advances in high-throughput techniques, and accessibility of
these methods, we envisage successful designs becoming
more commonplace in the coming years. In addition, new
methods of making synthetic components biocompatible
promise to unlock in vivo possibilities beyond those which
Nature can provide us. These biocompatible de novo units
may lead to improved and tailored medical benefits through
the design of drug delivery systems and therapeutic molecules.
In addition, we may learn more about how natural systemswork, and therefore increase our knowledge of natural
design principles in order to create improved de novo com-
ponents. Ultimately, we may be able to create tailor-made life
forms, such as bacteria with artificial genomes that can func-
tion in environments beyond their natural niches, to create,
for example, useful industrial products.
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